From Medscape Oncology

Coverage From The

European Hematology Association (EHA) 2019 Annual Meeting

June 13 - 16, 2019; Amsterdam, The Netherlands

June 13 - 16, 2019 Amsterdam, The Netherlands

EHA 2019 Novel Drug Targets Lymphoma Cells' 'Don't Eat Me' Signal The first-in-class agent Hu5F9 is a macrophage immune checkpoint inhibitor and, when added onto rituximab, shows potentially long-lasting efficacy in patients with relapsed and refractory lymphoma.
Medscape Medical News, June 19, 2019
EHA 2019 Novel Drug Could Be 'Disease Modifying' in Sickle Cell Disease An investigational agent, the first-in-class drug voxelotor, is seen as potentially ‘disease-modifying' as it targets mechanisms that cause anemia.
Medscape Medical News, June 17, 2019
EHA 2019 Measurable Residual Disease in AML Ups Post-HSCT Relapse Risk Measurable residual disease, detected with next-generation genomic sequencing, is associated with a significantly increased risk for relapse. Experts question the prognostic ability of other assessment tools.
Medscape Medical News, June 14, 2019

Conference News

EHA 2019 Acalabrutinib Now Finding a Role in CLL, Shows Good Tolerability
Medscape Medical News, June 28, 2019
EHA 2019 Venetoclax for Myeloma: Trial on Hold, Now Details of Benefit
Medscape Medical News, June 24, 2019
EHA 2019 Novel Drug Targets Lymphoma Cells' 'Don't Eat Me' Signal
Medscape Medical News, June 19, 2019
EHA 2019 Only 1 Year of Tx: Venetoclax/Obinutuzumab Combo in CLL
Medscape Medical News, June 18, 2019

EHA 2019 Daratumumab Boosts Outcomes in Newly Diagnosed Multiple Myeloma
Medscape Medical News, June 17, 2019
EHA 2019 Novel Drug Could Be 'Disease Modifying' in Sickle Cell Disease
Medscape Medical News, June 17, 2019
EHA 2019 Measurable Residual Disease in AML Ups Post-HSCT Relapse Risk
Medscape Medical News, June 14, 2019

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Popular News from EHA 2018

Vitamin D Deficiency and Reduced Hodgkin Lymphoma Survival A large study has found that patients with Hodgkin lymphoma who showed baseline deficiencies in vitamin D had significantly shorter progression-free and overall survival.
Medscape Medical News, Jun 18, 2018
New Drug for PHN Taken Only Once Every 8 Weeks Ravulizumab, a new drug for paroxysmal nocturnal hemoglobinuria (PNH), requires IV infusion only once every 8 weeks, compared with every 2 weeks for eculizumab, the only drug currently approved for this disorder.
Medscape Medical News, Jul 02, 2018
Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma A novel chemotherapy-free regimen containing lenalidomide and rituximab showed similar efficacy but less toxicity than the standard combination of rituximab and chemotherapy in the RELEVANCE trial.
Medscape Medical News, Jun 20, 2018

Previous Coverage